Obesity treatment: novel peripheral targets
暂无分享,去创建一个
[1] S. Bloom,et al. Investigation of structure-activity relationships of Oxyntomodulin (Oxm) using Oxm analogs. , 2009, Endocrinology.
[2] R. Collins,et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies , 2009, The Lancet.
[3] B. Bode,et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial , 2009, The Lancet.
[4] K. Ho,et al. Faculty Opinions recommendation of Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. , 2009 .
[5] D. Russell-Jones. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue , 2009, Molecular and Cellular Endocrinology.
[6] D. Drucker,et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study , 2008, The Lancet.
[7] L. Aronne,et al. Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity , 2008, Diabetes Care.
[8] M. Monteiro,et al. No evidence of an additive inhibitory feeding effect following PP and PYY3−36 administration , 2008, International Journal of Obesity.
[9] K. Elkind-Hirsch,et al. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. , 2008, The Journal of clinical endocrinology and metabolism.
[10] Christian Weyer,et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies , 2008, Proceedings of the National Academy of Sciences.
[11] SyedRizwanudden Ahmad,et al. Exenatide and rare adverse events. , 2008, The New England journal of medicine.
[12] M. Ruiz‐Gayo,et al. Leptin-mediated hypothalamic pathway of cholecystokinin (CCK-8) to regulate body weight in free-feeding rats. , 2008, Endocrinology.
[13] Lawrence A Leiter,et al. Stimulation of Cholecystokinin‐A Receptors With GI181771X does not Cause Weight Loss in Overweight or Obese Patients , 2008, Clinical pharmacology and therapeutics.
[14] S. Bloom,et al. Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake , 2008, Annals of clinical biochemistry.
[15] C. Weyer,et al. Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity. , 2007, Endocrinology.
[16] D. Ffytche,et al. PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans , 2007, Nature.
[17] J. Livingston,et al. Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. , 2007, Endocrinology.
[18] Astrid A. Ortiz,et al. Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. , 2007, Journal of medicinal chemistry.
[19] R. Quirion,et al. Distribution of Peripherally Injected Peptide YY ([125I] PYY (3–36)) and Pancreatic Polypeptide ([125I] hPP) in the CNS: Enrichment in the Area Postrema , 2007, Journal of Molecular Neuroscience.
[20] H. Jang,et al. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1 , 2007, Proceedings of the National Academy of Sciences.
[21] Steven C Hunt,et al. Long-term mortality after gastric bypass surgery. , 2007, The New England journal of medicine.
[22] M. Galyean,et al. Active immunization against ghrelin decreases weight gain and alters plasma concentrations of growth hormone in growing pigs. , 2007, Domestic animal endocrinology.
[23] P. Chelikani,et al. Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.
[24] S. Heymsfield,et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. , 2007, The Journal of clinical endocrinology and metabolism.
[25] G. Frost,et al. Low-dose pancreatic polypeptide inhibits food intake in man , 2007, British Journal of Nutrition.
[26] S. Majumdar,et al. Drug treatments for obesity: orlistat, sibutramine, and rimonabant , 2007, The Lancet.
[27] H. Inoue,et al. Effects of peripheral administration of PYY3-36 on feed intake and plasma acyl-ghrelin levels in pigs. , 2006, The Journal of endocrinology.
[28] M. Fujimiya,et al. Peptide YY3‐36 and pancreatic polypeptide suppress food intake , 2006, Journal of gastroenterology and hepatology.
[29] Jimmy D Bell,et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. , 2006, Cell metabolism.
[30] E. Zorrilla,et al. Vaccination against weight gain , 2006, Proceedings of the National Academy of Sciences.
[31] C. Seva,et al. Cholecystokinin and gastrin receptors. , 2006, Physiological reviews.
[32] Dennis D. Kim,et al. Long‐term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over‐weight metformin‐treated patients with type 2 diabetes mellitus , 2006, Diabetes, obesity & metabolism.
[33] G. Ferzli,et al. Laparoscopic gastric bypass is superior to adjustable gastric band in super morbidly obese patients: A prospective, comparative analysis. , 2006, Archives of surgery.
[34] C. Mcintosh,et al. Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY , 2006, Diabetologia.
[35] T. Schwartz,et al. The PP-fold solution structure of human polypeptide YY and human PYY3-36 as determined by NMR. , 2006, Biochemistry.
[36] D. Cottam,et al. A Case-Controlled Matched-Pair Cohort Study of Laparoscopic Roux-en-Y Gastric Bypass and Lap-Band® Patients in a Single US Center with Three-Year Follow-up , 2006, Obesity surgery.
[37] Josep Vidal,et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. , 2006, The Journal of clinical endocrinology and metabolism.
[38] G. Frost,et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial , 2006, International Journal of Obesity.
[39] S. Klußmann,et al. Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. , 2006, Endocrinology.
[40] P. S. Denker,et al. Exenatide (exendin-4)-induced pancreatitis: a case report. , 2006, Diabetes care.
[41] S. Bloom,et al. The importance of acclimatisation and habituation to experimental conditions when investigating the anorectic effects of gastrointestinal hormones in the rat , 2006, International Journal of Obesity.
[42] J. Holst,et al. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs , 2006, Diabetologia.
[43] R. Batterham,et al. Gut Hormone Profiles Following Bariatric Surgery Favor an Anorectic State, Facilitate Weight Loss, and Improve Metabolic Parameters , 2006, Annals of surgery.
[44] Mohammad A Ghatei,et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. , 2005, Endocrinology.
[45] R. L. Clark,et al. Peptide YY(3-36) inhibits morning, but not evening, food intake and decreases body weight in rhesus macaques. , 2005, Diabetes.
[46] D. Allison,et al. PYY3‐36 as an anti‐obesity drug target , 2005, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[47] Christoph Beglinger,et al. Effect of peptide YY3-36 on food intake in humans. , 2005, Gastroenterology.
[48] J. Holst,et al. A role for pancreatic polypeptide in the regulation of gastric emptying and short-term metabolic control. , 2005, The Journal of clinical endocrinology and metabolism.
[49] D. Drucker,et al. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. , 2005, Endocrinology.
[50] Karim Meeran,et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. , 2005, Diabetes.
[51] B. Klapp,et al. Anti-ghrelin Spiegelmer NOX-B11 inhibits neurostimulatory and orexigenic effects of peripheral ghrelin in rats , 2005, Gut.
[52] Dennis D. Kim,et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.
[53] K. Toshinai,et al. The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. , 2005, Endocrinology.
[54] Dennis D. Kim,et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. , 2005, Diabetes care.
[55] P. Chelikani,et al. Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats. , 2005, Endocrinology.
[56] T. Moran,et al. Peptide YY(3-36) inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.
[57] J. Griffith,et al. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. , 2005, JAMA.
[58] B. Beck,et al. Feeding response to ghrelin agonist and antagonist in lean and obese Zucker rats. , 2004, Life sciences.
[59] G. Frost,et al. Ghrelin increases food intake in obese as well as lean subjects , 2004, International Journal of Obesity.
[60] O G Kolterman,et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year, randomized controlled trial , 2004, Diabetic medicine : a journal of the British Diabetic Association.
[61] M. Tschöp,et al. Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[62] C. Beglinger,et al. Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.
[63] M. Vanderpump,et al. Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome. , 2004, The Journal of clinical endocrinology and metabolism.
[64] D. Drucker,et al. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. , 2004, Gastroenterology.
[65] A. Young,et al. Effects of PYY[3–36] in rodent models of diabetes and obesity , 2004, International Journal of Obesity.
[66] D. Allison,et al. Physiology: Does gut hormone PYY3–36 decrease food intake in rodents? , 2004, Nature.
[67] M. Low,et al. Physiology: Does gut hormone PYY3–36 decrease food intake in rodents? (reply) , 2004, Nature.
[68] N. Martin,et al. Pre-obese and obese agouti mice are sensitive to the anorectic effects of peptide YY3–36 but resistant to ghrelin , 2004, International Journal of Obesity.
[69] Mohammad A Ghatei,et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. , 2004, Endocrinology.
[70] J Dixon,et al. Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36). , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[71] T. Kigoshi,et al. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells , 2004, Autonomic Neuroscience.
[72] S. O’Rahilly,et al. Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. , 2003, Biochemical and biophysical research communications.
[73] T. Schwartz,et al. High constitutive signaling of the ghrelin receptor--identification of a potent inverse agonist. , 2003, Molecular endocrinology.
[74] Mohammad A Ghatei,et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. , 2003, The Journal of clinical endocrinology and metabolism.
[75] Mohammad A Ghatei,et al. Inhibition of food intake in obese subjects by peptide YY3-36. , 2003, The New England journal of medicine.
[76] D. Ryan,et al. Short-Term Food Restriction and Refeeding Alter Expression of Genes Likely Involved in Brain Glucosensing , 2003, Experimental biology and medicine.
[77] G. Frost,et al. Pancreatic polypeptide reduces appetite and food intake in humans. , 2003, The Journal of clinical endocrinology and metabolism.
[78] M. Fujimiya,et al. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice , 2003, Gut.
[79] M. Fujimiya,et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. , 2003, Gastroenterology.
[80] P. Hipskind,et al. Recent Developments in Our Understanding of the Physiological Role of PP-Fold Peptide Receptor Subtypes 1 , 2003, Experimental biology and medicine.
[81] C. Weyer,et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. , 2003, Diabetes care.
[82] K. Grove,et al. Orexin Neurons Express a Functional Pancreatic Polypeptide Y4 Receptor , 2003, The Journal of Neuroscience.
[83] K. Flegal,et al. Prevalence and trends in obesity among US adults, 1999-2000. , 2002, JAMA.
[84] K. Kangawa,et al. Ghrelin immunoreactivity in human plasma is suppressed by somatostatin , 2002, Clinical endocrinology.
[85] M. Papotti,et al. Ghrelin secretion is inhibited by either somatostatin or cortistatin in humans. , 2002, The Journal of clinical endocrinology and metabolism.
[86] Rachel L. Batterham,et al. Gut hormone PYY3-36 physiologically inhibits food intake , 2002, Nature.
[87] Mohammad A Ghatei,et al. Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. , 2002, American journal of physiology. Endocrinology and metabolism.
[88] S. Bloom,et al. Food fails to suppress ghrelin levels in obese humans. , 2002, The Journal of clinical endocrinology and metabolism.
[89] R. Ritter,et al. Daily CCK injection enhances reduction of body weight by chronic intracerebroventricular leptin infusion. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.
[90] B. Göke,et al. Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4. , 2002, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[91] C. Weyer,et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. , 2002, Diabetes care.
[92] T. Lutz,et al. Amylin potently activates AP neurons possibly via formation of the excitatory second messenger cGMP. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.
[93] G. Frost,et al. Ghrelin enhances appetite and increases food intake in humans. , 2001, The Journal of clinical endocrinology and metabolism.
[94] R. Batterham,et al. Ghrelin causes hyperphagia and obesity in rats. , 2001, Diabetes.
[95] P. J. Larsen,et al. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. , 2001, Diabetes.
[96] D. Smith,et al. Oxyntomodulin inhibits food intake in the rat. , 2001, Endocrinology.
[97] C. Beglinger,et al. Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.
[98] M. Nakazato,et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. , 2000, Endocrinology.
[99] M. Tschöp,et al. Ghrelin induces adiposity in rodents , 2000, Nature.
[100] P. Kopelman. Obesity as a medical problem , 2000, Nature.
[101] M. Nakazato,et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.
[102] M. Fujimiya,et al. Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice☆ , 1999, Peptides.
[103] J. Miyazaki,et al. Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. , 1999, Gastroenterology.
[104] M Morfis,et al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. , 1999, Molecular pharmacology.
[105] W. F. Mathes,et al. The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight. , 1999, The Journal of clinical investigation.
[106] J. Blundell,et al. Untangling the effects of hunger, anxiety, and nausea on energy intake during intravenous cholecystokinin octapeptide (CCK-8) infusion , 1998, Physiology & Behavior.
[107] Melanie G. Lee,et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor , 1998, Nature.
[108] A. Astrup,et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. , 1998, The Journal of clinical investigation.
[109] F. Ehrensperger,et al. Lesion of the Area Postrema/Nucleus of the Solitary Tract (AP/NTS) Attenuates the Anorectic Effects of Amylin and Calcitonin Gene-Related Peptide (CGRP) in Rats , 1998, Peptides.
[110] K. Beaumont,et al. Expression cloning and receptor pharmacology of human calcitonin receptors from MCF-7 cells and their relationship to amylin receptors. , 1997, Molecular pharmacology.
[111] P. J. Larsen,et al. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. , 1997, Endocrinology.
[112] R. M. Gentry,et al. Comparison of Fos induced in rat brain by GLP-1 and amylin , 1997, Regulatory Peptides.
[113] G. Schwartz,et al. Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin. , 1997, The American journal of physiology.
[114] J. Rehfeld,et al. Influence of meal composition on postprandial peripheral plasma concentrations of vasoactive peptides in man. , 1996, Scandinavian journal of clinical and laboratory investigation.
[115] P. J. Larsen,et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. , 1996, The American journal of physiology.
[116] D. Smith,et al. A role for glucagon-like peptide-1 in the central regulation of feeding , 1996, Nature.
[117] N. Geary,et al. Amylin decreases meal size in rats , 1995, Physiology & Behavior.
[118] R. Pederson,et al. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. , 1995, Endocrinology.
[119] G. Colditz,et al. Weight Gain as a Risk Factor for Clinical Diabetes Mellitus in Women , 1995, Annals of Internal Medicine.
[120] A. Masclee,et al. Satiety effects of a physiological dose of cholecystokinin in humans. , 1995, Gut.
[121] J. Jansen,et al. Satiety effects of cholecystokinin in humans. , 1994, Gastroenterology.
[122] C. Beglinger,et al. Two molecular forms of Peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1–36 and PYY 3–36 , 1994, Regulatory Peptides.
[123] P. Mantyh,et al. Cholecystokinin and neuropeptide Y receptors on single rabbit vagal afferent ganglion neurons: site of prejunctional modulation of visceral sensory neurons , 1994, Brain Research.
[124] Daniel Grandt,et al. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV , 1993, Regulatory Peptides.
[125] B. Gallwitz,et al. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. , 1993, European journal of biochemistry.
[126] G. Berntson,et al. Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome , 1993, Peptides.
[127] J. Jansen,et al. Effects of a physiological dose of cholecystokinin on food intake and postprandial satiation in man , 1993, Regulatory Peptides.
[128] B. Thorens. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[129] P. Blache,et al. Oxyntomodulin-like immunoreactivity: diurnal profile of a new potential enterogastrone. , 1992, The Journal of clinical endocrinology and metabolism.
[130] J. Holst,et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. , 1992, The New England journal of medicine.
[131] N. J. Andrews,et al. Human gut hormone profiles in patients with short bowel syndrome , 1992, Digestive diseases and sciences.
[132] J. Raufman,et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. , 1992, The Journal of biological chemistry.
[133] L. Bednarz,et al. Effects of selective CCK receptor agonists on food intake after central or peripheral administration in rats , 1992, Brain Research.
[134] G. Cooper,et al. Co-secretion of amylin and insulin from cultured islet beta-cells: modulation by nutrient secretagogues, islet hormones and hypoglycemic agents. , 1991, Biochemical and biophysical research communications.
[135] D. Whitcomb,et al. Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain. , 1990, The American journal of physiology.
[136] D. Martin,et al. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. , 1990, Annals of surgery.
[137] R. Rizza,et al. Effects of Meal Ingestion on Plasma Amylin Concentration in NIDDM and Nondiabetic Humans , 1990, Diabetes.
[138] G. Berntson,et al. Short-term infusion of pancreatic polypeptide: effect on children with Prader-Willi syndrome. , 1990, The American journal of clinical nutrition.
[139] Terry D. Lee,et al. A new molecular form of PYY: Structural characterization of human PYY(3–36) and PYY(1–36) , 1989, Peptides.
[140] S. Bloom,et al. GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.
[141] D. Bataille,et al. The effect of oxyntomodulin (Glucagon-37) and glucagon on exocrine pancreatic secretion in the conscious rat , 1987, Peptides.
[142] L. Orci,et al. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. , 1986, The Journal of biological chemistry.
[143] J M Polak,et al. Human distribution and release of a putative new gut hormone, peptide YY. , 1985, Gastroenterology.
[144] J. Polak,et al. Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry. , 1985, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[145] J. E. Morley,et al. Peptide YY (PYY), a poteny orexigenic agent , 1985, Brain Research.
[146] D. Maclean. Abrogation of peripheral cholecystokinin-satiety in the capsaicin treated rat , 1985, Regulatory Peptides.
[147] I. Goldfine,et al. Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. , 1985, The Journal of clinical investigation.
[148] R. Ritter,et al. Capsaicin pretreatment attenuates suppression of food intake by cholecystokinin. , 1985, The American journal of physiology.
[149] P S Kalra,et al. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. , 1984, Endocrinology.
[150] S. Woods,et al. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. , 1984, The American journal of physiology.
[151] W. Zipf,et al. Pancreatic polypeptide responses to protein meal challenges in obese but otherwise normal children and obese children with Prader-Willi syndrome. , 1983, The Journal of clinical endocrinology and metabolism.
[152] S. Bloom,et al. Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. , 1983, The Journal of clinical endocrinology and metabolism.
[153] J. Crawley,et al. Rapid development of tolerance to the behavioural actions of cholecystokinin , 1983, Nature.
[154] G. Bell,et al. Hamster preproglucagon contains the sequence of glucagon and two related peptides , 1983, Nature.
[155] T. Blundell,et al. Conformational flexibility in a small globular hormone: X‐ray analysis of avian pancreatic polypeptide at 0.98‐Å resolution , 1983, Biopolymers.
[156] X. Pi-Sunyer,et al. C-Terminal octapeptide of cholecystokinin decreases food intake in obese men , 1982, Physiology & Behavior.
[157] D. Bataille,et al. Oxyntomodulin (glucagon-37 or bioactive enteroglucagon): A potent inhibitor of pentagastrin-stimulated acid secretion in rats , 1982, Bioscience reports.
[158] G. Dockray,et al. Regional distributions of somatostatin and cholecystokinin-like immunoreactivities in rat and bovine brain , 1981, Peptides.
[159] W. Zipf,et al. Blunted pancreatic polypeptide responses in children with obesity of Prader-Willi syndrome. , 1981, The Journal of clinical endocrinology and metabolism.
[160] G. Dockray,et al. Neuropeptides in the gut: Quantification and characterization of cholecystokinin octapeptide-, bombesin- and vasoactive intestinal polypeptide-like immunoreactivities in the myenteric plexus of the guinea-pig small intestine , 1981, Peptides.
[161] G. P. Smith,et al. C-terminal octapeptide of cholecystokinin decreases food intake in man. , 1981, The American journal of clinical nutrition.
[162] D. Bataille,et al. ‘Enteroglucagon’: A specific effect on gastric glands isolated from the rat fundus. Evidence for an ‘oxyntomodulin’ action , 1981 .
[163] R. McLeod,et al. Human pancreatic polypeptide: studies of fasting and postprandial plasma concentrations. , 1980, Canadian journal of physiology and pharmacology.
[164] G. Greenberg,et al. Pharmacokinetics of pancreatic polypeptide in man. , 1978, Gut.
[165] J. Holst,et al. Vagal, cholinergic regulation of pancreatic polypeptide secretion. , 1978, The Journal of clinical investigation.
[166] L. Orci,et al. Pancreatic polypeptide: A possible role in the regulation of food intake in the mouse. Hypothesis , 1977, Experientia.
[167] T. Adrian,et al. Distribution and release of human pancreatic polypeptide. , 1976, Gut.
[168] J. Polak,et al. IDENTIFICATION OF CHOLECYSTOKININ-SECRETING CELLS , 1975, The Lancet.
[169] G. P. Smith,et al. Cholecystokinin decreases food intake in rats. , 1973, Journal of comparative and physiological psychology.
[170] B. Zinman,et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus ( LEAD-4 Met + TZD ) , 2009 .
[171] D. Dore,et al. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. , 2009, Current medical research and opinion.
[172] J. Leahy. A Double-Blind, Placebo-Controlled Trial Assessing Pramlintide Treatment in the Setting of Intensive Insulin Therapy in Type 1 Diabetes , 2007 .
[173] K. Wynne,et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. , 2006, Endocrinology.
[174] S. Adams,et al. PYY[3-36] administration decreases the respiratory quotient and reduces adiposity in diet-induced obese mice. , 2006, The Journal of nutrition.
[175] A. Sileno,et al. Lower mean weight after 14 days intravenous administration peptide YY3–36 (PYY3–36) in rabbits , 2006, International Journal of Obesity.
[176] J. Leahy,et al. Exenatide Versus Insulin Glargine in Patients With Suboptimally Controlled Type 2 Diabetes: A Randomized TrialHeine RJ, for the GWAA Study Group (VU Univ, Amsterdam; et al) Ann Intern Med 143:559–569, 2005§ , 2006 .
[177] G. Tsujimoto,et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120 , 2005, Nature Medicine.
[178] Peter T. Katzmarzyk,et al. Overweight and Obesity Mortality Trends in Canada, 1985–2000 , 2004, Canadian journal of public health = Revue canadienne de sante publique.
[179] F. Sundler,et al. Immunohistochemical localization of human pancreatic polypeptide (HPP) to a population of islet cells , 2004, Cell and Tissue Research.
[180] P. Proost,et al. Dipeptidyl peptidase IV substrates. An update on in vitro peptide hydrolysis by human DPPIV. , 2003, Advances in experimental medicine and biology.
[181] J. Rehfeld,et al. The predominant cholecystokinin in human plasma and intestine is cholecystokinin-33. , 2001, The Journal of clinical endocrinology and metabolism.
[182] J. Egan,et al. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. , 2000, Endocrinology.
[183] T. Rink,et al. Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. , 1996, Metabolism: clinical and experimental.
[184] B. Göke,et al. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. , 1995, Digestion.
[185] M. Wheeler,et al. The role of the free cytosolic calcium level in beta-cell signal transduction by gastric inhibitory polypeptide and glucagon-like peptide I(7-37). , 1993, Endocrinology.
[186] Graeme I. Bell,et al. Exon duplication and divergence in the human preproglucagon gene , 1983, Nature.
[187] V. Mutt,et al. Isolation of glucagon‐37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno‐ileum , 1982, FEBS letters.
[188] R. Gates,et al. The ability of pancreatic polypeptides (APP and BPP) to return to normal the hyperglycaemia, hyperinsulinaemia and weight gain of New Zealand obese mice. , 1977, Hormone research.
[189] P. Brubaker,et al. Printed in U.S.A. Copyright © 1999 by The Endocrine Society Role of the Vagus Nerve in Mediating Proximal Nutrient- Induced Glucagon-Like Peptide-1 Secretion* , 2022 .